| (3S,5R)-fluvastatin | multiple interactions | ISO | RGD:1317784 | 6480464 | fluvastatin inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| (S)-naringenin | multiple interactions | ISO | RGD:1317784 | 6480464 | naringenin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| 1,1-dichloroethene | decreases expression | EXP | | 6480464 | vinylidene chloride results in decreased expression of CYP2C11 protein | CTD | PMID:10547960 |
| 1,2-dichloroethene | decreases expression | EXP | | 6480464 | 1,2-dichloroethylene results in decreased expression of CYP2C11 protein | CTD | PMID:9493318 |
| 1,2-dichloroethene | decreases activity | EXP | | 6480464 | 1,2-dichloroethylene results in decreased activity of CYP2C11 protein | CTD | PMID:9493318 |
| 1,4-naphthoquinone | increases abundance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased abundance of 1,4-naphthoquinone | CTD | PMID:16243959 |
| 1-naphthol | increases abundance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased abundance of 1-naphthol | CTD | PMID:16243959 |
| 17alpha-ethynylestradiol | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Ethinyl Estradiol | CTD | PMID:15304426 |
| 17alpha-ethynylestradiol | decreases activity | EXP | | 6480464 | Ethinyl Estradiol results in decreased activity of CYP2C11 protein | CTD | PMID:12029382 PMID:11731036 |
| 17alpha-ethynylestradiol | decreases activity | EXP | | 6480464 | Ethinyl Estradiol results in decreased activity of CYP2C11 protein | CTD | PMID:11731036 PMID:12029382 |
| 17alpha-ethynylestradiol | decreases expression | EXP | | 6480464 | Ethinyl Estradiol results in decreased expression of CYP2C11 protein | CTD | PMID:11731036 |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of CYP2C11 mRNA | CTD | PMID:11553364 |
| 2,2',4,4',5,5'-hexachlorobiphenyl | increases expression | ISO | RGD:1322741 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP2C55 mRNA | CTD | PMID:20005886 |
| 2,2',4,4',5,5'-hexachlorobiphenyl | increases expression | ISO | RGD:1322741 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP2C55 mRNA | CTD | PMID:20005886 PMID:21851831 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1322741 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP2C11 mRNA | CTD | PMID:18467041 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1322741 | 6480464 | Tetrachlorodibenzodioxin affects the expression of CYP2C55 mRNA | CTD | PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CYP2C11 mRNA | CTD | PMID:21215274 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1322741 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP2C55 mRNA | CTD | PMID:20005886 PMID:19770486 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases activity | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased activity of CYP2C11 protein | CTD | PMID:16781091 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP2C11 mRNA | CTD | PMID:18467041 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | | 6480464 | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP2C11 mRNA] | CTD | PMID:18467041 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1317784 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CYP2C9 mRNA | CTD | PMID:16985168 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1322741 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP2C55 mRNA | CTD | PMID:19770486 PMID:20005886 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1322741 | 6480464 | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP2C11 mRNA] | CTD | PMID:18467041 |
| 2,4,6-trinitrobenzenesulfonic acid | multiple interactions | EXP | | 6480464 | gadolinium chloride inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP2C11 protein]; more ... | CTD | PMID:18079364 |
| 2-nitroanisole | increases oxidation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased oxidation of 2-nitroanisole | CTD | PMID:21218109 |
| 2-nitrophenol | increases oxidation | EXP | | 6480464 | CYP2C11 protein results in increased oxidation of 2-nitrophenol | CTD | PMID:20027144 |
| 3,3',5-triiodo-L-thyronine | multiple interactions | ISO | RGD:1317784 | 6480464 | Triiodothyronine promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins] | CTD | PMID:14557374 |
| 3-methylcholanthrene | multiple interactions | EXP | | 6480464 | Methylcholanthrene promotes the reaction [CYP2C11 protein results in increased oxidation of Toluene] | CTD | PMID:1994898 |
| 3-methylcholanthrene | decreases expression | EXP | | 6480464 | Methylcholanthrene results in decreased expression of CYP2C11 mRNA | CTD | PMID:10476907 |
| 4-hydroxytolbutamide | increases chemical synthesis | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased chemical synthesis of hydroxymethyltolbutamide | CTD | PMID:15155557 |
| 4-methylimidazole | multiple interactions | ISO | RGD:1317784 | 6480464 | 4-methylimidazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| 5,7-dihydroxy-4'-methoxyflavone | multiple interactions | ISO | RGD:1317784 | 6480464 | acacetin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| 7,12-dimethyltetraphene | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene | CTD | PMID:20507880 |
| 8'-apo-beta,psi-caroten-8'-al | increases expression | ISO | RGD:1317784 | 6480464 | apocarotenal results in increased expression of CYP2C9 mRNA | CTD | PMID:17034753 |
| acenocoumarol | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Acenocoumarol | CTD | PMID:11918509 |
| acenocoumarol | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the susceptibility to Acenocoumarol | CTD | PMID:15213846 more ... |
| acenocoumarol | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the susceptibility to Acenocoumarol | CTD | PMID:15213846 more ... |
| acenocoumarol | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the susceptibility to Acenocoumarol | CTD | PMID:19578179 more ... |
| acenocoumarol | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the susceptibility to Acenocoumarol | CTD | PMID:16878445 more ... |
| acenocoumarol | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the susceptibility to Acenocoumarol | CTD | PMID:18698879 more ... |
| acenocoumarol | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Acenocoumarol | CTD | PMID:16878445 |
| acetone | multiple interactions | ISO | RGD:1317784 | 6480464 | Acetone promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] | CTD | PMID:10611138 |
| acetonitrile | multiple interactions | ISO | RGD:1317784 | 6480464 | acetonitrile promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] | CTD | PMID:10611138 |
| acetonitrile | multiple interactions | EXP | | 6480464 | acetonitrile inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] | CTD | PMID:19858067 |
| acetylsalicylic acid | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 polymorphism affects the susceptibility to Aspirin | CTD | PMID:21966608 |
| aconitine | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Aconitine | CTD | PMID:21277363 |
| aconitine | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C9 protein results in increased metabolism of Aconitine] which results in increased chemical synthesis of 16-O-demethylaconitine; more ... | CTD | PMID:21277363 |
| aflatoxin B1 | affects expression | ISO | RGD:1317784 | 6480464 | Aflatoxin B1 affects the expression of CYP2C9 protein | CTD | PMID:20106945 |
| aflatoxin B1 | increases expression | ISO | RGD:1317784 | 6480464 | Aflatoxin B1 results in increased expression of CYP2C9 mRNA | CTD | PMID:21994236 |
| aflatoxin B1 | increases activity | EXP | | 6480464 | CYP2C11 protein results in increased activity of Aflatoxin B1 | CTD | PMID:11346484 |
| aflatoxin B1 | decreases expression | ISO | RGD:1322741 | 6480464 | Aflatoxin B1 results in decreased expression of CYP2C55 mRNA | CTD | PMID:19770486 |
| all-trans-retinoic acid | decreases expression | ISO | RGD:1317784 | 6480464 | Tretinoin results in decreased expression of CYP2C9 mRNA | CTD | PMID:16985168 |
| all-trans-retinol | multiple interactions | EXP | | 6480464 | GH1 protein promotes the reaction [Vitamin A affects the expression of and affects the activity of CYP2C11 protein] | CTD | PMID:15963505 |
| allyl alcohol | decreases expression | EXP | | 6480464 | allyl alcohol results in decreased expression of CYP2C11 protein | CTD | PMID:10547960 |
| alpha-hexachlorocyclohexane | multiple interactions | EXP | | 6480464 | [Diethylnitrosamine co-treated with alpha-hexachlorocyclohexane] results in increased expression of CYP2C11 mRNA; more ... | CTD | PMID:16246485 |
| alpha-linolenic acid | decreases activity | ISO | RGD:1317784 | 6480464 | alpha-Linolenic Acid results in decreased activity of CYP2C9 protein | CTD | PMID:16978661 |
| alpha-linolenic acid | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] | CTD | PMID:16978661 |
| amiodarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Amiodarone inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; more ... | CTD | PMID:16081671 |
| amiodarone | multiple interactions | ISO | RGD:1317784 | 6480464 | [Amiodarone results in decreased activity of CYP2C9 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine; more ... | CTD | PMID:21277363 |
| amiodarone | decreases activity | ISO | RGD:1317784 | 6480464 | Amiodarone results in decreased activity of CYP2C9 protein | CTD | PMID:16449812 |
| amiodarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Amiodarone promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins] | CTD | PMID:14557374 |
| amodiaquine | decreases activity | ISO | RGD:1317784 | 6480464 | Amodiaquine results in decreased activity of CYP2C9 protein | CTD | PMID:11124226 |
| andrographolide | decreases expression | ISO | RGD:1317784 | 6480464 | andrographolide results in decreased expression of CYP2C9 mRNA | CTD | PMID:19041297 |
| andrographolide | decreases expression | EXP | | 6480464 | andrographolide results in decreased expression of CYP2C11 protein; more ... | CTD | PMID:19041297 |
| apigenin | multiple interactions | ISO | RGD:1317784 | 6480464 | Apigenin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| arachidonic acid | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP] | CTD | PMID:16978661 |
| arachidonic acid | decreases activity | ISO | RGD:1317784 | 6480464 | Arachidonic Acid results in decreased activity of CYP2C9 protein | CTD | PMID:16978661 |
| aristolochic acid | multiple interactions | EXP | | 6480464 | [CYP2C11 protein co-treated with CYB5A protein] results in increased abundance of aristolochic acid I metabolite; more ... | CTD | PMID:21362632 |
| atrazine | decreases activity | EXP | | 6480464 | Atrazine results in decreased activity of CYP2C11 protein | CTD | PMID:9711812 |
| baicalein | multiple interactions | ISO | RGD:1317784 | 6480464 | baicalein inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| benzbromarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Benzbromarone analog binds to and results in decreased activity of CYP2C9 protein | CTD | PMID:12814975 PMID:15170332 |
| benzbromarone | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Benzbromarone | CTD | PMID:18020424 PMID:21321060 |
| benzbromarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Benzbromarone inhibits the reaction [CYP2C9 protein polymorphism affects the hydroxylation of Flurbiprofen]; more ... | CTD | PMID:15955872 |
| benzbromarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Benzbromarone inhibits the reaction [CYP2C9 protein affects the metabolism of Warfarin] | CTD | PMID:10613612 |
| benzbromarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Benzbromarone inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; more ... | CTD | PMID:16081671 |
| benzbromarone | affects binding | ISO | RGD:1317784 | 6480464 | Benzbromarone binds to CYP2C9 protein | CTD | PMID:12814975 |
| benzbromarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Benzbromarone binds to and results in decreased activity of CYP2C9 protein | CTD | PMID:15170332 |
| benzbromarone | multiple interactions | ISO | RGD:1317784 | 6480464 | Benzbromarone analog binds to and results in decreased activity of CYP2C9 protein | CTD | PMID:15170332 PMID:12814975 |
| benzbromarone | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Benzbromarone | CTD | PMID:21321060 PMID:18020424 |
| benzene | decreases expression | EXP | | 6480464 | Benzene results in decreased expression of CYP2C11 protein | CTD | PMID:8135039 |
| benzo[a]pyrene | increases expression | ISO | RGD:1322741 | 6480464 | Benzo(a)pyrene results in increased expression of CYP2C55 mRNA | CTD | PMID:19770486 PMID:20127859 |
| benzo[a]pyrene | increases expression | ISO | RGD:1322741 | 6480464 | Benzo(a)pyrene results in increased expression of CYP2C55 mRNA | CTD | PMID:20127859 PMID:19770486 |
| benzophenone | increases expression | EXP | | 6480464 | benzophenone results in increased expression of CYP2C11 mRNA | CTD | PMID:14613717 |
| beta-carotene | increases expression | ISO | RGD:1317784 | 6480464 | beta Carotene results in increased expression of CYP2C9 mRNA | CTD | PMID:17034753 |
| bilirubin | increases expression | ISO | RGD:1317784 | 6480464 | Bilirubin results in increased expression of CYP2C9 mRNA | CTD | PMID:15382119 |
| bilirubin | multiple interactions | ISO | RGD:1317784 | 6480464 | IL1B protein inhibits the reaction [Bilirubin results in increased expression of CYP2C9 mRNA] | CTD | PMID:15382119 |
| bis(2-ethylhexyl) phthalate | increases expression | ISO | RGD:1322741 | 6480464 | Diethylhexyl Phthalate results in increased expression of CYP2C55 mRNA | CTD | PMID:19850644 |
| bis(2-ethylhexyl) phthalate | multiple interactions | ISO | RGD:1322741 | 6480464 | PPARA protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of CYP2C55 mRNA] | CTD | PMID:19850644 |
| bromobenzene | decreases expression | EXP | | 6480464 | bromobenzene results in decreased expression of CYP2C11 protein | CTD | PMID:10547960 |
| cadmium atom | increases expression | ISO | RGD:1317784 | 6480464 | Cadmium results in increased expression of CYP2C9 protein | CTD | PMID:11551516 |
| calciol | increases expression | ISO | RGD:1317784 | 6480464 | Cholecalciferol metabolite results in increased expression of CYP2C9 | CTD | PMID:11991950 |
| capsaicin | decreases activity | ISO | RGD:1317784 | 6480464 | Capsaicin results in decreased activity of CYP2C9 protein | CTD | PMID:22375877 |
| carbamazepine | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Carbamazepine | CTD | PMID:15286053 |
| carbamazepine | increases activity | ISO | RGD:1317784 | 6480464 | Carbamazepine results in increased activity of CYP2C9 protein | CTD | PMID:19202563 |
| carbamazepine | increases expression | ISO | RGD:1317784 | 6480464 | Carbamazepine results in increased expression of CYP2C9 mRNA | CTD | PMID:17112801 |
| celecoxib | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of celecoxib | CTD | PMID:17681167 |
| celecoxib | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of celecoxib | CTD | PMID:17681167 PMID:19082874 |
| chlorpromazine | decreases expression | EXP | | 6480464 | Chlorpromazine results in decreased expression of CYP2C11 mRNA | CTD | PMID:18246545 |
| chlorpromazine | decreases activity | ISO | RGD:1317784 | 6480464 | Chlorpromazine results in decreased activity of CYP2C9 protein | CTD | PMID:15135088 |
| chlorzoxazone | affects metabolic processing | EXP | | 6480464 | CYP2C11 protein affects the metabolism of Chlorzoxazone | CTD | PMID:15879494 |
| cimetidine | multiple interactions | EXP | | 6480464 | Cimetidine inhibits the reaction [CYP2C11 protein results in increased glutathionylation of lamotrigine] | CTD | PMID:19961160 |
| cimetidine | decreases activity | ISO | RGD:1317784 | 6480464 | Cimetidine results in decreased activity of CYP2C9 protein | CTD | PMID:19909766 |
| cimetidine | multiple interactions | ISO | RGD:1317784 | 6480464 | styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP2C9 protein] | CTD | PMID:19909766 |
| cinnamic acid | decreases activity | ISO | RGD:1317784 | 6480464 | cinnamic acid analog results in decreased activity of CYP2C9 protein | CTD | PMID:15072549 |
| ciprofloxacin | decreases expression | EXP | | 6480464 | Ciprofloxacin results in decreased expression of CYP2C11 mRNA | CTD | PMID:12621481 |
| cis-ketoconazole | multiple interactions | ISO | RGD:1317784 | 6480464 | Ketoconazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| cis-ketoconazole | decreases activity | ISO | RGD:1317784 | 6480464 | Ketoconazole results in decreased activity of CYP2C9 protein | CTD | PMID:14709627 PMID:15618748 |
| cis-ketoconazole | decreases activity | EXP | | 6480464 | Ketoconazole results in decreased activity of CYP2C11 protein | CTD | PMID:15879494 |
| cis-ketoconazole | multiple interactions | EXP | | 6480464 | Ketoconazole inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] | CTD | PMID:19858067 |
| cis-ketoconazole | decreases activity | ISO | RGD:1317784 | 6480464 | Ketoconazole results in decreased activity of CYP2C9 protein | CTD | PMID:15618748 PMID:14709627 |
| cisapride | decreases activity | ISO | RGD:1317784 | 6480464 | Cisapride results in decreased activity of CYP2C9 protein | CTD | PMID:15306208 |
| cisplatin | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the susceptibility to Cisplatin | CTD | PMID:16217747 |
| clofibric acid | multiple interactions | EXP | | 6480464 | Clofibric Acid results in decreased expression of and results in decreased activity of CYP2C11 protein; more ... | CTD | PMID:15788368 |
| clofibric acid | increases expression | ISO | RGD:1317784 | 6480464 | Clofibric Acid results in increased expression of CYP2C9 mRNA | CTD | PMID:15802389 |
| clofibric acid | decreases expression | EXP | | 6480464 | Clofibric Acid results in decreased expression of CYP2C11 mRNA | CTD | PMID:15788368 |
| clotrimazole | multiple interactions | EXP | | 6480464 | Clotrimazole inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] | CTD | PMID:19858067 |
| clotrimazole | multiple interactions | ISO | RGD:1317784 | 6480464 | Clotrimazole results in increased activity of and results in increased expression of CYP2C9 protein | CTD | PMID:19202563 |
| clotrimazole | multiple interactions | ISO | RGD:1317784 | 6480464 | Clotrimazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| clotrimazole | decreases expression | EXP | | 6480464 | Clotrimazole results in decreased expression of CYP2C11 protein | CTD | PMID:7986207 |
| clozapine | multiple interactions | ISO | RGD:1317784 | 6480464 | [Clozapine results in decreased activity of CYP2C9 protein] which results in increased susceptibility to Phenytoin | CTD | PMID:17961958 |
| cocaine | decreases expression | ISO | RGD:1317784 | 6480464 | Cocaine results in decreased expression of CYP2C9 mRNA; more ... | CTD | PMID:16188404 |
| copper atom | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C9 protein co-treated with Copper] results in increased activity of Eugenol | CTD | PMID:15576237 |
| copper(0) | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C9 protein co-treated with Copper] results in increased activity of Eugenol | CTD | PMID:15576237 |
| coumarin | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein polymorphism affects the metabolism of coumarin | CTD | PMID:17849045 |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CYP2C9 protein] | CTD | PMID:16288784 |
| cyclophosphamide | increases expression | EXP | | 6480464 | Cyclophosphamide results in increased expression of CYP2C11 mRNA | CTD | PMID:16019949 |
| cyclophosphamide | increases metabolic processing | EXP | | 6480464 | CYP2C11 results in increased metabolism of Cyclophosphamide | CTD | PMID:20566340 |
| cyclophosphamide | multiple interactions | ISO | RGD:1317784 | 6480464 | Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased susceptibility to Cyclophosphamide] | CTD | PMID:10991840 |
| cyclophosphamide | increases activity | ISO | RGD:1317784 | 6480464 | CYP2C9 results in increased activity of Cyclophosphamide | CTD | PMID:9241661 |
| cyclophosphamide | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased susceptibility to Cyclophosphamide | CTD | PMID:10991840 |
| cyclophosphamide | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Cyclophosphamide | CTD | PMID:11377097 |
| cyclosporin A | decreases expression | ISO | RGD:1322741 | 6480464 | Cyclosporine results in decreased expression of CYP2C55 mRNA | CTD | PMID:19770486 |
| cyclosporin A | decreases expression | ISO | RGD:1317784 | 6480464 | Cyclosporine results in decreased expression of CYP2C9 mRNA | CTD | PMID:20106945 |
| cypermethrin | increases expression | ISO | RGD:1317784 | 6480464 | cypermethrin results in increased expression of CYP2C9 mRNA | CTD | PMID:22310298 |
| dapsone | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Dapsone | CTD | PMID:12920490 |
| dapsone | decreases activity | ISO | RGD:1317784 | 6480464 | Dapsone results in decreased activity of CYP2C9 protein | CTD | PMID:11124226 |
| dapsone | multiple interactions | ISO | RGD:1317784 | 6480464 | Dapsone promotes the reaction [CYP2C9 protein polymorphism results in decreased methylation of Naproxen]; more ... | CTD | PMID:15130760 |
| delavirdine | decreases activity | ISO | RGD:1317784 | 6480464 | Delavirdine results in decreased activity of CYP2C9 protein | CTD | PMID:11225565 |
| Delta(9)-tetrahydrocannabinol | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 polymorphism affects the susceptibility to Tetrahydrocannabinol | CTD | PMID:19005461 |
| deoxycholic acid | decreases expression | EXP | | 6480464 | Deoxycholic Acid results in decreased expression of CYP2C11 protein | CTD | PMID:10453939 |
| deoxycholic acid | multiple interactions | EXP | | 6480464 | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C11 protein] | CTD | PMID:10453939 |
| desipramine | decreases activity | ISO | RGD:1317784 | 6480464 | Desipramine results in decreased activity of CYP2C9 protein | CTD | PMID:15135088 |
| dexamethasone | increases expression | EXP | | 6480464 | Dexamethasone results in increased expression of CYP2C11 | CTD | PMID:15890479 |
| dexamethasone | increases activity | ISO | RGD:1317784 | 6480464 | Dexamethasone results in increased activity of CYP2C9 protein | CTD | PMID:19202563 |
| dexamethasone | increases expression | ISO | RGD:1317784 | 6480464 | Dexamethasone results in increased expression of CYP2C9 mRNA | CTD | PMID:15802389 |
| dexamethasone | multiple interactions | ISO | RGD:1317784 | 6480464 | Dexamethasone results in increased expression of and results in increased activity of CYP2C9 protein | CTD | PMID:15802389 |
| dexamethasone | increases expression | EXP | | 6480464 | Dexamethasone results in increased expression of CYP2C11 protein | CTD | PMID:19041297 |
| diazinon | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of and results in increased activity of Diazinon | CTD | PMID:11708902 |
| diazoxide | decreases expression | EXP | | 6480464 | Isoproterenol results in decreased expression of CYP2C11 mRNA | CTD | PMID:18725507 |
| dibenz[a,h]anthracene | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C9 protein results in increased metabolism of 1,2,5,6-dibenzanthracene] which results in increased chemical synthesis of dibenzoanthracene-3,4-dihydrodiol | CTD | PMID:8638931 |
| dibenz[a,h]anthracene | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of 1,2,5,6-dibenzanthracene | CTD | PMID:8638931 |
| diclofenac | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Diclofenac | CTD | PMID:12401345 more ... |
| diclofenac | increases hydrolysis | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydrolysis of Diclofenac | CTD | PMID:9698079 |
| diclofenac | affects hydrolysis | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the hydrolysis of Diclofenac | CTD | PMID:9698079 |
| diclofenac | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Diclofenac | CTD | PMID:10975605 more ... |
| diclofenac | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Diclofenac | CTD | PMID:12401345 more ... |
| diclofenac | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Diclofenac | CTD | PMID:15155557 more ... |
| diclofenac | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Diclofenac | CTD | PMID:9110362 more ... |
| diclofenac | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Diclofenac | CTD | PMID:16081671 PMID:15801540 |
| diclofenac | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Diclofenac | CTD | PMID:15860655 more ... |
| diclofenac | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Diclofenac | CTD | PMID:17418993 more ... |
| diclofenac | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Diclofenac | CTD | PMID:11455026 more ... |
| diclofenac | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Diclofenac | CTD | PMID:20452209 more ... |
| diclofenac | affects metabolic processing | EXP | | 6480464 | CYP2C9 protein affects the metabolism of Diclofenac | CTD | PMID:15801540 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | Ticrynafen inhibits the reaction [CYP2C9 protein results in increased metabolism of Diclofenac] | CTD | PMID:16049126 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | perfluorooctane sulfonic acid inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] | CTD | PMID:21964418 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | lansoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac]; more ... | CTD | PMID:15258107 |
| diclofenac | increases activity | ISO | RGD:1317784 | 6480464 | Diclofenac results in increased activity of CYP2C9 protein | CTD | PMID:15802386 |
| diclofenac | decreases activity | ISO | RGD:1317784 | 6480464 | Diclofenac results in decreased activity of CYP2C9 protein | CTD | PMID:15135088 |
| diclofenac | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Diclofenac | CTD | PMID:20452209 more ... |
| diclofenac | increases oxidation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased oxidation of Diclofenac | CTD | PMID:17478480 |
| diclofenac | affects binding | ISO | RGD:1317784 | 6480464 | CYP2C9 protein binds to Diclofenac | CTD | PMID:15039296 |
| diclofenac | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Diclofenac | CTD | PMID:21964418 more ... |
| diclofenac | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Diclofenac | CTD | PMID:15801540 PMID:16081671 |
| diclofenac | decreases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased hydroxylation of Diclofenac | CTD | PMID:11455026 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C19 protein co-treated with CYP2C9 protein] results in increased hydroxylation of Diclofenac | CTD | PMID:15486075 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | Cyclohexenes analog inhibits the reaction [CYP2C9 protein results in increased metabolism of Diclofenac] | CTD | PMID:20452209 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | 4-methylimidazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; more ... | CTD | PMID:16081671 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | 1-aminobenzotriazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] | CTD | PMID:15618748 |
| diclofenac | multiple interactions | ISO | RGD:1317784 | 6480464 | Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Diclofenac] | CTD | PMID:12569440 |
| diclofenamide | multiple interactions | ISO | RGD:1317784 | 6480464 | Dichlorphenamide promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins] | CTD | PMID:14557374 |
| dihydrocapsaicin | decreases activity | ISO | RGD:1317784 | 6480464 | dihydrocapsaicin results in decreased activity of CYP2C9 protein | CTD | PMID:22375877 |
| dimethyl sulfoxide | multiple interactions | EXP | | 6480464 | Dimethyl Sulfoxide inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] | CTD | PMID:19858067 |
| dimethyl sulfoxide | multiple interactions | ISO | RGD:1322741 | 6480464 | NR1I3 gene mutant form inhibits the reaction [[Phenobarbital co-treated with Dimethyl Sulfoxide] results in increased expression of CYP2C55 protein]; more ... | CTD | PMID:20371638 |
| dioxygen | decreases expression | ISO | RGD:1317784 | 6480464 | Oxygen deficiency results in decreased expression of CYP2C9 mRNA | CTD | PMID:19695866 |
| disulfiram | decreases activity | EXP | | 6480464 | Disulfiram results in decreased activity of CYP2C11 protein | CTD | PMID:9393675 |
| disulfiram | decreases expression | EXP | | 6480464 | Disulfiram results in decreased expression of CYP2C11 protein | CTD | PMID:9393675 |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of CYP2C11 protein; more ... | CTD | PMID:19796650 |
| ethanol | multiple interactions | EXP | | 6480464 | Ethanol promotes the reaction [CYP2C11 protein results in increased oxidation of Toluene] | CTD | PMID:1994898 |
| ethanol | increases expression | ISO | RGD:1322741 | 6480464 | Ethanol results in increased expression of CYP2C55 mRNA | CTD | PMID:19167417 |
| ethylbenzene | decreases expression | EXP | | 6480464 | ethylbenzene results in decreased expression of CYP2C11 protein | CTD | PMID:8135039 |
| eugenol | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C9 protein co-treated with Copper] results in increased activity of Eugenol | CTD | PMID:15576237 |
| farnesol | increases activity | EXP | | 6480464 | Farnesol results in increased activity of CYP2C11 protein | CTD | PMID:15840382 |
| fenvalerate | increases expression | ISO | RGD:1317784 | 6480464 | fenvalerate results in increased expression of CYP2C9 mRNA | CTD | PMID:22310298 |
| flavanone | multiple interactions | ISO | RGD:1317784 | 6480464 | flavanone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| flavone | multiple interactions | ISO | RGD:1317784 | 6480464 | flavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| flavonol | multiple interactions | ISO | RGD:1317784 | 6480464 | 3-hydroxyflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| fluconazole | increases expression | ISO | RGD:1322741 | 6480464 | Fluconazole results in increased expression of CYP2C55 mRNA | CTD | PMID:16730040 |
| fluconazole | multiple interactions | ISO | RGD:1317784 | 6480464 | Fluconazole affects the reaction [CYP2C9 gene polymorphism affects the metabolism of Flurbiprofen] | CTD | PMID:18378563 |
| fluconazole | decreases activity | ISO | RGD:1317784 | 6480464 | Fluconazole results in decreased activity of CYP2C9 protein | CTD | PMID:15328084 PMID:15843491 |
| fluconazole | decreases activity | ISO | RGD:1317784 | 6480464 | Fluconazole results in decreased activity of CYP2C9 protein | CTD | PMID:15843491 PMID:15328084 |
| fluconazole | multiple interactions | ISO | RGD:1317784 | 6480464 | Fluconazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| fluoxetine | multiple interactions | EXP | | 6480464 | Fluoxetine inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] | CTD | PMID:19858067 |
| fluoxetine | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Fluoxetine | CTD | PMID:14726986 |
| fluoxetine | affects abundance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the abundance of Fluoxetine | CTD | PMID:14726986 |
| fluoxetine | affects abundance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the abundance of Fluoxetine | CTD | PMID:15094477 |
| fluphenazine | decreases activity | ISO | RGD:1317784 | 6480464 | Fluphenazine results in decreased activity of CYP2C9 protein | CTD | PMID:15135088 |
| flurbiprofen | multiple interactions | ISO | RGD:1317784 | 6480464 | Benzbromarone inhibits the reaction [CYP2C9 protein polymorphism affects the hydroxylation of Flurbiprofen]; more ... | CTD | PMID:15955872 |
| flurbiprofen | affects hydrolysis | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the hydrolysis of Flurbiprofen | CTD | PMID:9698079 |
| flurbiprofen | increases hydrolysis | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydrolysis of Flurbiprofen | CTD | PMID:9698079 |
| flurbiprofen | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the metabolism of Flurbiprofen | CTD | PMID:11901091 PMID:18378563 |
| flurbiprofen | multiple interactions | ISO | RGD:1317784 | 6480464 | Fluconazole affects the reaction [CYP2C9 gene polymorphism affects the metabolism of Flurbiprofen] | CTD | PMID:18378563 |
| flurbiprofen | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Flurbiprofen | CTD | PMID:11901091 more ... |
| flurbiprofen | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Flurbiprofen | CTD | PMID:15130760 PMID:21053930 |
| flurbiprofen | affects binding | ISO | RGD:1317784 | 6480464 | Flurbiprofen binds to CYP2C9 protein | CTD | PMID:21053930 |
| flurbiprofen | multiple interactions | ISO | RGD:1317784 | 6480464 | 3',4'-dimethoxyflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen]; more ... | CTD | PMID:21053930 |
| flurbiprofen | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Flurbiprofen | CTD | PMID:21053930 PMID:15130760 |
| flurbiprofen | affects hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the hydroxylation of Flurbiprofen | CTD | PMID:15955872 |
| flurbiprofen | multiple interactions | ISO | RGD:1317784 | 6480464 | Dapsone promotes the reaction [CYP2C9 protein polymorphism results in increased hydroxylation of Flurbiprofen]; more ... | CTD | PMID:15130760 |
| flurbiprofen | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Flurbiprofen; more ... | CTD | PMID:15130760 |
| fulvestrant | increases expression | EXP | | 6480464 | fulvestrant results in increased expression of CYP2C11 mRNA | CTD | PMID:16837770 |
| gadolinium trichloride | multiple interactions | EXP | | 6480464 | gadolinium chloride inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP2C11 protein] | CTD | PMID:18079364 |
| galangin | multiple interactions | ISO | RGD:1317784 | 6480464 | galangin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| gamma-hexachlorocyclohexane | increases expression | EXP | | 6480464 | Lindane results in increased expression of CYP2C11 mRNA | CTD | PMID:16837770 |
| gamma-hexachlorocyclohexane | increases expression | EXP | | 6480464 | Lindane results in increased expression of CYP2C11 protein | CTD | PMID:11684361 |
| genistein | multiple interactions | ISO | RGD:1317784 | 6480464 | Genistein inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| hyperforin | multiple interactions | ISO | RGD:1317784 | 6480464 | hyperforin results in increased expression of and results in increased activity of CYP2C9 protein | CTD | PMID:15100173 |
| hyperforin | increases expression | ISO | RGD:1317784 | 6480464 | hyperforin results in increased expression of CYP2C9 mRNA | CTD | PMID:15100173 PMID:14600250 |
| hyperforin | multiple interactions | ISO | RGD:1317784 | 6480464 | NR1I2 protein affects the reaction [hyperforin results in increased expression of CYP2C9 mRNA] | CTD | PMID:14600250 |
| hyperforin | increases expression | ISO | RGD:1317784 | 6480464 | hyperforin results in increased expression of CYP2C9 mRNA | CTD | PMID:14600250 PMID:15100173 |
| ibuprofen | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Ibuprofen | CTD | PMID:18694831 PMID:15289789 |
| ibuprofen | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Ibuprofen | CTD | PMID:15289789 PMID:18694831 |
| ibuprofen | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Ibuprofen | CTD | PMID:12464242 PMID:17681167 |
| ibuprofen | multiple interactions | ISO | RGD:1317784 | 6480464 | Ibuprofen inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| ibuprofen | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Ibuprofen | CTD | PMID:17681167 PMID:12464242 |
| ibuprofen | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein polymorphism affects the metabolism of Ibuprofen | CTD | PMID:12152005 |
| ibuprofen | affects binding | ISO | RGD:1317784 | 6480464 | CYP2C9 protein binds to Ibuprofen | CTD | PMID:15039296 |
| ifosfamide | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased susceptibility to Ifosfamide | CTD | PMID:20507880 |
| ifosfamide | increases activity | ISO | RGD:1317784 | 6480464 | CYP2C9 results in increased activity of Ifosfamide | CTD | PMID:9241661 |
| indomethacin | decreases expression | EXP | | 6480464 | Indomethacin results in decreased expression of CYP2C11 mRNA | CTD | PMID:16771604 |
| irbesartan | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of irbesartan | CTD | PMID:12359989 |
| irbesartan | decreases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased susceptibility to irbesartan | CTD | PMID:12359989 |
| isoprenaline | decreases expression | EXP | | 6480464 | Isoproterenol results in decreased expression of CYP2C11 mRNA | CTD | PMID:18725507 |
| kaempferol | multiple interactions | ISO | RGD:1317784 | 6480464 | kaempferol inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| lamotrigine | increases activity | EXP | | 6480464 | CYP2C11 protein results in increased activity of lamotrigine | CTD | PMID:19961160 |
| lamotrigine | increases glutathionylation | EXP | | 6480464 | CYP2C11 protein results in increased glutathionylation of lamotrigine | CTD | PMID:19961160 |
| lamotrigine | multiple interactions | EXP | | 6480464 | Cimetidine inhibits the reaction [CYP2C11 protein results in increased glutathionylation of lamotrigine] | CTD | PMID:19961160 |
| lansoprazole | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of lansoprazole | CTD | PMID:8627562 PMID:12975331 |
| lansoprazole | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of lansoprazole | CTD | PMID:12975331 PMID:8627562 |
| lansoprazole | multiple interactions | ISO | RGD:1317784 | 6480464 | lansoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] | CTD | PMID:15258107 |
| lauric acid | decreases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased hydroxylation of lauric acid | CTD | PMID:11455026 |
| lauric acid | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of lauric acid | CTD | PMID:11455026 PMID:9241660 |
| lauric acid | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of lauric acid | CTD | PMID:9241660 PMID:11455026 |
| lead(0) | decreases expression | ISO | RGD:1317784 | 6480464 | Lead results in decreased expression of CYP2C9 mRNA | CTD | PMID:19921347 |
| losartan | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Losartan | CTD | PMID:21321060 |
| losartan | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Losartan | CTD | PMID:19082874 more ... |
| losartan | multiple interactions | ISO | RGD:1317784 | 6480464 | resveratrol inhibits the reaction [CYP2C9 protein results in increased metabolism of Losartan] | CTD | PMID:20716633 |
| losartan | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Losartan | CTD | PMID:19082874 PMID:19715737 |
| losartan | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Losartan | CTD | PMID:19715737 |
| mangiferin | decreases activity | ISO | RGD:1317784 | 6480464 | mangiferin results in decreased activity of CYP2C9 protein | CTD | PMID:22815239 |
| methapyrilene | decreases activity | EXP | | 6480464 | Methapyrilene results in decreased activity of CYP2C11 protein | CTD | PMID:9928682 |
| methoxsalen | decreases activity | EXP | | 6480464 | Methoxsalen results in decreased activity of CYP2C11 protein | CTD | PMID:12814958 PMID:15879494 |
| methoxsalen | decreases activity | EXP | | 6480464 | Methoxsalen results in decreased activity of CYP2C11 protein | CTD | PMID:15879494 PMID:12814958 |
| methoxychlor | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C19 protein co-treated with CYP2C9 protein] results in decreased methylation of Methoxychlor | CTD | PMID:15486075 |
| methoxychlor | increases expression | EXP | | 6480464 | Methoxychlor results in increased expression of CYP2C11 mRNA | CTD | PMID:14613717 |
| methoxychlor | decreases expression | EXP | | 6480464 | Methoxychlor results in decreased expression of CYP2C11 protein | CTD | PMID:12919727 |
| methoxychlor | decreases activity | EXP | | 6480464 | Methoxychlor results in decreased activity of CYP2C11 protein | CTD | PMID:8114062 |
| methoxychlor | increases metabolic processing | EXP | | 6480464 | CYP2C11 protein results in increased metabolism of Methoxychlor | CTD | PMID:14613717 |
| methoxychlor | decreases methylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in decreased methylation of Methoxychlor | CTD | PMID:9733665 |
| methylarsonic acid | increases expression | EXP | | 6480464 | monomethylarsonic acid results in increased expression of CYP2C11 mRNA | CTD | PMID:17481689 |
| miconazole | multiple interactions | ISO | RGD:1317784 | 6480464 | Miconazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| miconazole | decreases activity | ISO | RGD:1317784 | 6480464 | Miconazole results in decreased activity of CYP2C9 protein | CTD | PMID:15328084 |
| mitomycin C | decreases activity | EXP | | 6480464 | Mitomycin results in decreased activity of CYP2C11 protein | CTD | PMID:15696929 |
| mono(2-ethylhexyl) phthalate | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate | CTD | PMID:22186153 |
| mono(2-ethylhexyl) phthalate | multiple interactions | ISO | RGD:1317784 | 6480464 | [CYP2C9 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate; more ... | CTD | PMID:22186153 |
| N,N-dimethylformamide | decreases expression | EXP | | 6480464 | Dimethylformamide results in decreased expression of CYP2C11 protein | CTD | PMID:10547960 |
| N-nitrosodiethylamine | decreases expression | EXP | | 6480464 | Diethylnitrosamine results in decreased expression of CYP2C11 mRNA | CTD | PMID:20360939 PMID:14965361 |
| N-nitrosodiethylamine | decreases expression | EXP | | 6480464 | Diethylnitrosamine results in decreased expression of CYP2C11 mRNA | CTD | PMID:14965361 more ... |
| N-nitrosodiethylamine | decreases expression | EXP | | 6480464 | Diethylnitrosamine results in decreased expression of CYP2C11 mRNA | CTD | PMID:14965361 PMID:20360939 |
| N-nitrosodiethylamine | multiple interactions | EXP | | 6480464 | [Diethylnitrosamine co-treated with alpha-hexachlorocyclohexane] results in increased expression of CYP2C11 protein; more ... | CTD | PMID:16246485 |
| NADP zwitterion | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; more ... | CTD | PMID:16978661 |
| NADP(+) | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; more ... | CTD | PMID:16978661 |
| naphthalene | increases expression | ISO | RGD:1317784 | 6480464 | naphthalene results in increased expression of CYP2C9 mRNA | CTD | PMID:20500019 |
| naproxen | multiple interactions | ISO | RGD:1317784 | 6480464 | Amiodarone promotes the reaction [CYP2C9 protein affects the metabolism of Naproxen]; more ... | CTD | PMID:16081671 |
| naproxen | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Naproxen | CTD | PMID:11901091 more ... |
| naproxen | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the metabolism of Naproxen | CTD | PMID:11901091 |
| naproxen | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Naproxen | CTD | PMID:17681167 PMID:12464242 |
| naproxen | multiple interactions | ISO | RGD:1317784 | 6480464 | Dapsone promotes the reaction [CYP2C9 protein polymorphism results in decreased methylation of Naproxen]; more ... | CTD | PMID:15130760 |
| naproxen | decreases methylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein polymorphism results in decreased methylation of Naproxen; more ... | CTD | PMID:15130760 |
| naproxen | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Naproxen | CTD | PMID:12464242 PMID:17681167 |
| naproxen | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Naproxen | CTD | PMID:16081671 |
| naringin | multiple interactions | ISO | RGD:1317784 | 6480464 | naringin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| nevirapine | affects binding | EXP | | 6480464 | Nevirapine binds to CYP2C11 protein | CTD | PMID:22793666 |
| ochratoxin A | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased susceptibility to ochratoxin A | CTD | PMID:21781659 |
| ochratoxin A | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased susceptibility to ochratoxin A | CTD | PMID:8542584 PMID:21781659 |
| ochratoxin A | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased susceptibility to ochratoxin A | CTD | PMID:21781659 PMID:8542584 |
| ochratoxin A | increases expression | ISO | RGD:1317784 | 6480464 | ochratoxin A results in increased expression of CYP2C9 mRNA | CTD | PMID:21834667 |
| omeprazole | multiple interactions | ISO | RGD:1317784 | 6480464 | Omeprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] | CTD | PMID:15258107 |
| paclitaxel | decreases activity | ISO | RGD:1317784 | 6480464 | Paclitaxel results in decreased activity of CYP2C9 protein | CTD | PMID:19909766 |
| paclitaxel | increases activity | ISO | RGD:1317784 | 6480464 | Paclitaxel results in increased activity of CYP2C9 protein | CTD | PMID:19202563 |
| pantoprazole | multiple interactions | ISO | RGD:1317784 | 6480464 | pantoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] | CTD | PMID:15258107 |
| paracetamol | affects expression | ISO | RGD:1322741 | 6480464 | Acetaminophen affects the expression of CYP2C55 mRNA | CTD | PMID:17562736 |
| paracetamol | increases expression | ISO | RGD:1317784 | 6480464 | Acetaminophen results in increased expression of CYP2C9 mRNA | CTD | PMID:22230336 |
| paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of CYP2C11 mRNA | CTD | PMID:17126469 PMID:21807079 |
| paracetamol | multiple interactions | EXP | | 6480464 | [Acetaminophen co-treated with Uranium analog] results in decreased expression of CYP2C11 mRNA | CTD | PMID:17126469 |
| paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of CYP2C11 mRNA | CTD | PMID:17126469 |
| parathion | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Parathion | CTD | PMID:17079358 |
| pentamidine | decreases activity | ISO | RGD:1317784 | 6480464 | Pentamidine results in decreased activity of CYP2C9 protein | CTD | PMID:11124226 |
| perazine | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the metabolism of Perazine | CTD | PMID:11026737 |
| perazine | decreases methylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in decreased methylation of Perazine | CTD | PMID:11026737 |
| perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:1317784 | 6480464 | perfluorooctane sulfonic acid inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] | CTD | PMID:21964418 |
| perfluorooctane-1-sulfonic acid | increases expression | ISO | RGD:1322741 | 6480464 | perfluorooctane sulfonic acid results in increased expression of CYP2C55 mRNA | CTD | PMID:20936131 |
| perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:1322741 | 6480464 | PPARA protein inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CYP2C55 mRNA] | CTD | PMID:20936131 |
| perfluorooctanoic acid | affects expression | ISO | RGD:1322741 | 6480464 | perfluorooctanoic acid affects the expression of CYP2C55 mRNA | CTD | PMID:18281256 |
| perfluorooctanoic acid | multiple interactions | ISO | RGD:1322741 | 6480464 | PPARA protein inhibits the reaction [perfluorooctanoic acid results in increased expression of CYP2C55 mRNA] | CTD | PMID:20936131 |
| perfluorooctanoic acid | increases expression | ISO | RGD:1322741 | 6480464 | perfluorooctanoic acid results in increased expression of CYP2C55 mRNA | CTD | PMID:18467677 PMID:20936131 |
| perfluorooctanoic acid | increases expression | ISO | RGD:1322741 | 6480464 | perfluorooctanoic acid results in increased expression of CYP2C55 mRNA | CTD | PMID:18467677 |
| phenacetin | affects metabolic processing | EXP | | 6480464 | CYP2C11 protein affects the metabolism of Phenacetin | CTD | PMID:15879494 |
| phencyclidine | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Phencyclidine | CTD | PMID:16782764 |
| phenobarbital | multiple interactions | ISO | RGD:1322741 | 6480464 | NR1I3 protein affects the reaction [Phenobarbital results in increased expression of CYP2C55 mRNA] | CTD | PMID:19482888 |
| phenobarbital | increases expression | ISO | RGD:1322741 | 6480464 | Phenobarbital results in increased expression of CYP2C55 mRNA | CTD | PMID:19270015 more ... |
| phenobarbital | multiple interactions | ISO | RGD:1322741 | 6480464 | NR1I3 gene mutant form inhibits the reaction [[Phenobarbital co-treated with Dimethyl Sulfoxide] results in increased expression of CYP2C55 mRNA]; more ... | CTD | PMID:20371638 |
| phenobarbital | increases activity | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased activity of CYP2C9 protein | CTD | PMID:19328226 |
| phenobarbital | increases expression | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased expression of CYP2C9 mRNA | CTD | PMID:15629111 more ... |
| phenobarbital | increases activity | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased activity of CYP2C9 mRNA | CTD | PMID:19202563 |
| phenobarbital | multiple interactions | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased activity of and results in increased expression of CYP2C9 protein | CTD | PMID:19202563 |
| phenobarbital | increases expression | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased expression of CYP2C9 mRNA | CTD | PMID:15629111 more ... |
| phenobarbital | decreases activity | ISO | RGD:1317784 | 6480464 | Phenobarbital results in decreased activity of CYP2C9 protein | CTD | PMID:19909766 |
| phenobarbital | increases expression | ISO | RGD:1322741 | 6480464 | Phenobarbital results in increased expression of CYP2C55 mRNA | CTD | PMID:19270015 more ... |
| phenobarbital | increases expression | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased expression of CYP2C9 mRNA | CTD | PMID:15802389 more ... |
| phenobarbital | increases expression | ISO | RGD:1322741 | 6480464 | Phenobarbital results in increased expression of CYP2C55 mRNA | CTD | PMID:20403969 more ... |
| phenobarbital | increases expression | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased expression of CYP2C9 mRNA | CTD | PMID:15629111 PMID:15802389 |
| phenobarbital | increases expression | ISO | RGD:1322741 | 6480464 | Phenobarbital results in increased expression of CYP2C55 mRNA | CTD | PMID:20403969 more ... |
| phenobarbital | increases activity | EXP | | 6480464 | Phenobarbital results in increased activity of CYP2C11 protein | CTD | PMID:16781091 |
| phenobarbital | multiple interactions | EXP | | 6480464 | Phenobarbital promotes the reaction [CYP2C11 protein results in increased oxidation of Toluene] | CTD | PMID:1994898 |
| phenobarbital | multiple interactions | EXP | | 6480464 | Phenobarbital affects the expression of and affects the activity of CYP2C11 protein | CTD | PMID:12807726 |
| phenobarbital | increases expression | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased expression of CYP2C9 mRNA | CTD | PMID:15802389 PMID:15629111 |
| phenobarbital | multiple interactions | ISO | RGD:1317784 | 6480464 | Phenobarbital results in increased expression of and results in increased activity of CYP2C9 protein | CTD | PMID:15802389 |
| phenobarbital | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the metabolism of Phenobarbital | CTD | PMID:17304159 |
| phenobarbital | increases expression | ISO | RGD:1322741 | 6480464 | Phenobarbital results in increased expression of CYP2C55 mRNA | CTD | PMID:19270015 more ... |
| phenprocoumon | affects response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the susceptibility to Phenprocoumon | CTD | PMID:18698879 |
| phenprocoumon | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Phenprocoumon | CTD | PMID:19082874 |
| phenytoin | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 5' UTR polymorphism results in decreased metabolism of Phenytoin | CTD | PMID:11503012 |
| phenytoin | increases activity | ISO | RGD:1317784 | 6480464 | Phenytoin results in increased activity of CYP2C9 protein | CTD | PMID:19202563 |
| phenytoin | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Phenytoin | CTD | PMID:16873909 more ... |
| phenytoin | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Phenytoin | CTD | PMID:10208645 more ... |
| phenytoin | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Phenytoin | CTD | PMID:10208645 more ... |
| phenytoin | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Phenytoin | CTD | PMID:11668218 more ... |
| phenytoin | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Phenytoin | CTD | PMID:9110362 more ... |
| phenytoin | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Phenytoin | CTD | PMID:11740344 more ... |
| phenytoin | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Phenytoin | CTD | PMID:2025243 more ... |
| phenytoin | decreases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased hydroxylation of Phenytoin | CTD | PMID:9860067 PMID:16873909 |
| phenytoin | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Phenytoin | CTD | PMID:10510154 more ... |
| phenytoin | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Phenytoin | CTD | PMID:16220110 more ... |
| phenytoin | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Phenytoin | CTD | PMID:10208645 more ... |
| phenytoin | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Phenytoin | CTD | PMID:16873909 more ... |
| phenytoin | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Phenytoin | CTD | PMID:11434505 more ... |
| phenytoin | increases metabolic processing | EXP | | 6480464 | CYP2C9 protein results in increased metabolism of Phenytoin | CTD | PMID:15569425 |
| phenytoin | increases expression | ISO | RGD:1317784 | 6480464 | Phenytoin results in increased expression of CYP2C9 mRNA | CTD | PMID:14600250 |
| phenytoin | multiple interactions | ISO | RGD:1317784 | 6480464 | NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP2C9 mRNA] | CTD | PMID:14600250 |
| phenytoin | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Phenytoin | CTD | PMID:10208645 more ... |
| phenytoin | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Phenytoin | CTD | PMID:15855726 |
| phenytoin | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in increased susceptibility to Phenytoin | CTD | PMID:11740344 |
| phenytoin | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Phenytoin | CTD | PMID:9860067 more ... |
| phenytoin | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Phenytoin | CTD | PMID:10208645 more ... |
| phenytoin | decreases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased hydroxylation of Phenytoin | CTD | PMID:16873909 PMID:9860067 |
| phenytoin | multiple interactions | ISO | RGD:1317784 | 6480464 | [Clozapine results in decreased activity of CYP2C9 protein] which results in increased susceptibility to Phenytoin | CTD | PMID:17961958 |
| pirinixic acid | decreases expression | ISO | RGD:1322741 | 6480464 | pirinixic acid results in decreased expression of CYP2C11 protein | CTD | PMID:17405874 |
| pirinixic acid | decreases expression | ISO | RGD:1322741 | 6480464 | pirinixic acid results in decreased expression of CYP2C55 mRNA | CTD | PMID:18445702 PMID:20813756 |
| pirinixic acid | decreases expression | ISO | | 6480464 | pirinixic acid results in decreased expression of CYP2C11 protein | CTD | PMID:17405874 |
| pirinixic acid | decreases expression | ISO | RGD:1322741 | 6480464 | pirinixic acid results in decreased expression of CYP2C55 mRNA | CTD | PMID:20813756 PMID:18445702 |
| piroxicam | multiple interactions | ISO | RGD:1317784 | 6480464 | Piroxicam inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| piroxicam | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Piroxicam | CTD | PMID:11901091 more ... |
| piroxicam | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the metabolism of Piroxicam | CTD | PMID:11901091 |
| piroxicam | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Piroxicam | CTD | PMID:17681167 PMID:12464242 |
| poly(styrene) | decreases activity | ISO | RGD:1317784 | 6480464 | styrofoam analog results in decreased activity of CYP2C9 protein | CTD | PMID:19909766 |
| poly(styrene) | multiple interactions | ISO | RGD:1317784 | 6480464 | styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP2C9 protein] | CTD | PMID:19909766 |
| polymyxin B2 | multiple interactions | EXP | | 6480464 | Polymyxin B inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP2C11 protein] | CTD | PMID:18079364 |
| pregnenolone 16alpha-carbonitrile | multiple interactions | ISO | RGD:1322741 | 6480464 | NR1I2 protein promotes the reaction [Pregnenolone Carbonitrile results in increased expression of CYP2C55 mRNA] | CTD | PMID:22698814 |
| pregnenolone 16alpha-carbonitrile | increases expression | ISO | RGD:1322741 | 6480464 | Pregnenolone Carbonitrile results in increased expression of CYP2C55 mRNA | CTD | PMID:20371638 PMID:22698814 |
| pregnenolone 16alpha-carbonitrile | multiple interactions | ISO | RGD:1322741 | 6480464 | NR1I2 gene mutant form inhibits the reaction [Pregnenolone Carbonitrile results in increased expression of CYP2C55 mRNA] | CTD | PMID:20371638 |
| pregnenolone 16alpha-carbonitrile | increases expression | ISO | RGD:1322741 | 6480464 | Pregnenolone Carbonitrile results in increased expression of CYP2C55 mRNA | CTD | PMID:22698814 |
| propiconazole | increases expression | ISO | RGD:1322741 | 6480464 | propiconazole results in increased expression of CYP2C55 mRNA | CTD | PMID:16730040 PMID:21278054 |
| propiconazole | increases expression | ISO | RGD:1322741 | 6480464 | propiconazole results in increased expression of CYP2C55 mRNA | CTD | PMID:16730040 more ... |
| propiconazole | increases expression | ISO | RGD:1322741 | 6480464 | propiconazole results in increased expression of CYP2C55 mRNA | CTD | PMID:21278054 PMID:16730040 |
| propiconazole | decreases expression | EXP | | 6480464 | propiconazole results in decreased expression of CYP2C11 protein | CTD | PMID:7986207 |
| propranolol | increases oxidation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased oxidation of Propranolol | CTD | PMID:19853591 |
| propylbenzene | decreases expression | EXP | | 6480464 | n-propylbenzene results in decreased expression of CYP2C11 protein | CTD | PMID:8135039 |
| pyrimethamine | decreases activity | ISO | RGD:1317784 | 6480464 | Pyrimethamine results in decreased activity of CYP2C9 protein | CTD | PMID:11124226 |
| pyrimidin-2-amine | affects binding | EXP | | 6480464 | 2-aminopyrimidine analog binds to CYP2C11 protein | CTD | PMID:19317514 |
| quercetin | multiple interactions | ISO | RGD:1317784 | 6480464 | Quercetin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] | CTD | PMID:21053930 |
| quercetin | increases expression | ISO | RGD:1317784 | 6480464 | Quercetin results in increased expression of CYP2C9 mRNA | CTD | PMID:21632981 |
| quinine | decreases activity | ISO | RGD:1317784 | 6480464 | Quinine results in decreased activity of CYP2C9 protein | CTD | PMID:11124226 |
| quinine | decreases activity | EXP | | 6480464 | Quinine results in decreased activity of CYP2C11 protein | CTD | PMID:12814958 PMID:15879494 |
| quinine | decreases activity | EXP | | 6480464 | Quinine results in decreased activity of CYP2C11 protein | CTD | PMID:15879494 PMID:12814958 |
| quinine | multiple interactions | ISO | RGD:1317784 | 6480464 | Quinine inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| rel-(3R,5S)-fluvastatin | multiple interactions | ISO | RGD:1317784 | 6480464 | fluvastatin inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| resveratrol | multiple interactions | ISO | RGD:1317784 | 6480464 | resveratrol inhibits the reaction [CYP2C9 protein results in increased metabolism of Losartan] | CTD | PMID:20716633 |
| rifampicin | multiple interactions | ISO | RGD:1317784 | 6480464 | NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA] | CTD | PMID:14600250 |
| rifampicin | increases activity | ISO | RGD:1317784 | 6480464 | Rifampin results in increased activity of CYP2C9 protein | CTD | PMID:14722322 more ... |
| rifampicin | increases activity | ISO | RGD:1317784 | 6480464 | Rifampin results in increased activity of CYP2C9 protein | CTD | PMID:14722322 more ... |
| rifampicin | multiple interactions | ISO | RGD:1317784 | 6480464 | NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; more ... | CTD | PMID:21292004 |
| rifampicin | multiple interactions | ISO | RGD:1317784 | 6480464 | Rifampin results in increased activity of and results in increased expression of CYP2C9 protein | CTD | PMID:19202563 |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 mRNA | CTD | PMID:14600250 more ... |
| rifampicin | increases activity | ISO | RGD:1317784 | 6480464 | Rifampin results in increased activity of CYP2C9 protein | CTD | PMID:14722322 PMID:19497360 |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 mRNA | CTD | PMID:14600250 more ... |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 mRNA | CTD | PMID:15629111 more ... |
| rifampicin | multiple interactions | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of and results in increased activity of CYP2C9 protein | CTD | PMID:14709624 PMID:15802389 |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 mRNA | CTD | PMID:15629111 more ... |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 protein | CTD | PMID:17590308 PMID:19041297 |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 mRNA | CTD | PMID:17954527 more ... |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 protein | CTD | PMID:19041297 PMID:17590308 |
| rifampicin | increases expression | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of CYP2C9 mRNA | CTD | PMID:15802389 more ... |
| rifampicin | multiple interactions | ISO | RGD:1317784 | 6480464 | Rifampin results in increased expression of and results in increased activity of CYP2C9 protein | CTD | PMID:15802389 PMID:14709624 |
| rifampicin | increases activity | ISO | RGD:1317784 | 6480464 | Rifampin results in increased activity of CYP2C9 protein | CTD | PMID:14722322 |
| sertraline | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in decreased methylation of and results in increased metabolism of Sertraline | CTD | PMID:15547048 |
| sertraline | multiple interactions | ISO | RGD:1317784 | 6480464 | Sertraline inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| sevoflurane | affects expression | EXP | | 6480464 | sevoflurane affects the expression of CYP2C11 mRNA | CTD | PMID:15967596 |
| silymarin | decreases activity | ISO | RGD:1317784 | 6480464 | silybin results in decreased activity of CYP2C9 protein | CTD | PMID:15155549 |
| simazine | decreases activity | EXP | | 6480464 | Simazine results in decreased activity of CYP2C11 protein | CTD | PMID:9711812 |
| styrene | decreases expression | EXP | | 6480464 | Styrene results in decreased expression of CYP2C11 mRNA | CTD | PMID:16418063 |
| styrene oxide | multiple interactions | EXP | | 6480464 | CYP2C11 protein promotes the reaction [EPHX1 protein affects the hydrolysis of styrene oxide] | CTD | PMID:12051674 |
| succimer | multiple interactions | ISO | RGD:1322741 | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in increased expression of CYP2C55 mRNA | CTD | PMID:21641980 |
| Sudan I | increases oxidation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased oxidation of 1-phenylazo-2-naphthol | CTD | PMID:17159775 |
| sulfadiazine | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Sulfadiazine | CTD | PMID:15843491 |
| sulfinpyrazone | multiple interactions | ISO | RGD:1317784 | 6480464 | Sulfinpyrazone inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| tamoxifen | multiple interactions | EXP | | 6480464 | Tamoxifen promotes the reaction [testosterone enanthate results in increased expression of CYP2C11 protein] | CTD | PMID:8573203 |
| testosterone | affects metabolic processing | EXP | | 6480464 | CYP2C11 protein affects the metabolism of Testosterone | CTD | PMID:15879494 |
| testosterone | increases expression | EXP | | 6480464 | Testosterone results in increased expression of CYP2C11 mRNA | CTD | PMID:16837770 |
| testosterone enanthate | multiple interactions | EXP | | 6480464 | Tamoxifen promotes the reaction [testosterone enanthate results in increased expression of CYP2C11 protein] | CTD | PMID:8573203 |
| testosterone enanthate | increases expression | EXP | | 6480464 | testosterone enanthate results in increased expression of CYP2C11 protein | CTD | PMID:8573203 |
| testosterone enanthate | increases expression | EXP | | 6480464 | testosterone enanthate results in increased expression of CYP2C11 mRNA | CTD | PMID:8819526 |
| tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of CYP2C11 mRNA | CTD | PMID:14706259 |
| tetrachloromethane | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CYP2C9 protein] | CTD | PMID:16288784 |
| tetrachloromethane | decreases activity | EXP | | 6480464 | Carbon Tetrachloride results in decreased activity of CYP2C9 protein | CTD | PMID:16288784 |
| tetrachloromethane | decreases activity | EXP | | 6480464 | Carbon Tetrachloride results in decreased activity of CYP2C11 protein | CTD | PMID:14706259 |
| tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of CYP2C11 protein | CTD | PMID:17606319 |
| thiabendazole | decreases activity | ISO | RGD:1317784 | 6480464 | Thiabendazole results in decreased activity of CYP2C9 protein | CTD | PMID:11124226 |
| thioridazine | decreases activity | ISO | RGD:1317784 | 6480464 | Thioridazine results in decreased activity of CYP2C9 protein | CTD | PMID:15135088 |
| ticlopidine | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite | CTD | PMID:19170597 |
| tolbutamide | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Tolbutamide | CTD | PMID:9110362 PMID:10208645 |
| tolbutamide | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Tolbutamide | CTD | PMID:10208645 more ... |
| tolbutamide | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Tolbutamide | CTD | PMID:10611138 more ... |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Tolbutamide | CTD | PMID:11875364 more ... |
| tolbutamide | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Tolbutamide | CTD | PMID:2025243 more ... |
| tolbutamide | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Tolbutamide | CTD | PMID:12464242 more ... |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Tolbutamide | CTD | PMID:11875364 more ... |
| tolbutamide | decreases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism results in decreased metabolism of Tolbutamide | CTD | PMID:10208645 PMID:9110362 |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene SNP affects the metabolism of Tolbutamide | CTD | PMID:12426520 PMID:11875364 |
| tolbutamide | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Tolbutamide | CTD | PMID:15843491 more ... |
| tolbutamide | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Tolbutamide | CTD | PMID:17702393 more ... |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Tolbutamide | CTD | PMID:15626586 more ... |
| tolbutamide | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Tolbutamide | CTD | PMID:17702393 more ... |
| tolbutamide | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Tolbutamide | CTD | PMID:9522436 more ... |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Tolbutamide | CTD | PMID:15626586 more ... |
| tolbutamide | affects hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the hydroxylation of Tolbutamide | CTD | PMID:9170147 |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene SNP affects the metabolism of Tolbutamide | CTD | PMID:11875364 PMID:12426520 |
| tolbutamide | decreases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 gene SNP results in decreased hydroxylation of Tolbutamide | CTD | PMID:9170147 |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 gene polymorphism affects the metabolism of Tolbutamide | CTD | PMID:15045499 |
| tolbutamide | multiple interactions | ISO | RGD:1317784 | 6480464 | Tolbutamide inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| tolbutamide | multiple interactions | ISO | RGD:1317784 | 6480464 | Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased hydrolysis of Tolbutamide] | CTD | PMID:11377097 |
| tolbutamide | multiple interactions | ISO | RGD:1317784 | 6480464 | pranlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; more ... | CTD | PMID:15370959 |
| tolbutamide | increases hydroxylation | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydroxylation of Tolbutamide | CTD | PMID:9110362 more ... |
| tolbutamide | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Tolbutamide | CTD | PMID:17267297 more ... |
| tolbutamide | increases hydrolysis | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased hydrolysis of Tolbutamide | CTD | PMID:11377097 |
| tolbutamide | multiple interactions | ISO | RGD:1317784 | 6480464 | CYP2C9 protein binds to and affects the metabolism of Tolbutamide | CTD | PMID:15856409 |
| tolbutamide | affects metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein affects the metabolism of Tolbutamide | CTD | PMID:15626586 PMID:15327588 |
| tolbutamide | multiple interactions | ISO | RGD:1317784 | 6480464 | acetonitrile promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; more ... | CTD | PMID:10611138 |
| toluene | increases oxidation | EXP | | 6480464 | CYP2C11 protein results in increased oxidation of Toluene | CTD | PMID:1994898 |
| toluene | multiple interactions | EXP | | 6480464 | Ethanol promotes the reaction [CYP2C11 protein results in increased oxidation of Toluene]; more ... | CTD | PMID:1994898 |
| trans-1,2-dichloroethene | decreases expression | EXP | | 6480464 | 1,2-dichloroethylene results in decreased expression of CYP2C11 protein | CTD | PMID:9493318 |
| trans-1,2-dichloroethene | decreases activity | EXP | | 6480464 | 1,2-dichloroethylene results in decreased activity of CYP2C11 protein | CTD | PMID:9493318 |
| trans-resveratrol | multiple interactions | ISO | RGD:1317784 | 6480464 | resveratrol inhibits the reaction [CYP2C9 protein results in increased metabolism of Losartan] | CTD | PMID:20716633 |
| trimethylarsine oxide | increases expression | EXP | | 6480464 | trimethylarsine oxide results in increased expression of CYP2C11 mRNA | CTD | PMID:17481689 |
| troglitazone | decreases activity | ISO | RGD:1317784 | 6480464 | troglitazone results in decreased activity of CYP2C9 protein | CTD | PMID:12642470 |
| uranium atom | multiple interactions | EXP | | 6480464 | [Acetaminophen co-treated with Uranium analog] results in decreased expression of CYP2C11 mRNA | CTD | PMID:17126469 |
| ursodeoxycholic acid | multiple interactions | EXP | | 6480464 | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C11 protein] | CTD | PMID:10453939 |
| valproic acid | affects expression | ISO | RGD:1322741 | 6480464 | Valproic Acid affects the expression of CYP2C55 mRNA | CTD | PMID:17292431 |
| valproic acid | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Valproic Acid | CTD | PMID:16945988 PMID:20602621 |
| valproic acid | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 polymorphism results in increased susceptibility to Valproic Acid | CTD | PMID:20398172 |
| valproic acid | increases metabolic processing | ISO | RGD:1317784 | 6480464 | CYP2C9 protein results in increased metabolism of Valproic Acid | CTD | PMID:16945988 |
| vincristine | increases response to substance | ISO | RGD:1317784 | 6480464 | CYP2C9 gene SNP results in increased susceptibility to Vincristine | CTD | PMID:21245421 |
| zafirlukast | decreases activity | ISO | RGD:1317784 | 6480464 | zafirlukast results in decreased activity of CYP2C9 protein | CTD | PMID:15370959 |
| zafirlukast | multiple interactions | ISO | RGD:1317784 | 6480464 | zafirlukast inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] | CTD | PMID:16081671 |
| zafirlukast | multiple interactions | ISO | RGD:1317784 | 6480464 | zafirlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide] | CTD | PMID:15370959 |
| zinc atom | multiple interactions | EXP | | 6480464 | Zinc deficiency results in decreased expression of and results in decreased activity of CYP2C11 protein | CTD | PMID:11705462 |
| zinc atom | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of CYP2C11 mRNA | CTD | PMID:11705462 |
| zinc(0) | multiple interactions | EXP | | 6480464 | Zinc deficiency results in decreased expression of and results in decreased activity of CYP2C11 protein | CTD | PMID:11705462 |
| zinc(0) | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of CYP2C11 mRNA | CTD | PMID:11705462 |